Daliresp Sales Pitch Draws FDA Letter After Forest Fails To Heed Advisory Comments

The agency says the violation occurred despite FDA’s criticism of proposed promotional material for the respiratory drug and an ongoing corporate integrity agreement intended to block improper promotion.